↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

Overview of attention for article published in Clinical Pharmacology & Therapeutics, August 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
15 tweeters
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
164 Dimensions

Readers on

mendeley
144 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
Published in
Clinical Pharmacology & Therapeutics, August 2014
DOI 10.1038/clpt.2014.159
Pubmed ID
Authors

K E Caudle, A E Rettie, M Whirl-Carrillo, L H Smith, S Mintzer, M T M Lee, T E Klein, J T Callaghan

Abstract

Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large interpatient variability, partly due to genetic variations in the gene encoding cytochrome P450 (CYP)2C9 (CYP2C9). Furthermore, the variant allele HLA-B*15:02, encoding human leukocyte antigen, is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this guideline is to provide information for the interpretation of HLA-B and/or CYP2C9 genotype tests so that the results can guide dosing and/or use of phenytoin. Detailed guidelines for the use of phenytoin as well as analyses of cost-effectiveness are out of scope. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are periodically updated at http://www.pharmgkb.org.Clinical Pharmacology & Therapeutics (2014); advance online publication 17 September 2014. doi:10.1038/clpt.2014.159.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 143 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 27 19%
Researcher 24 17%
Student > Ph. D. Student 17 12%
Student > Bachelor 16 11%
Student > Doctoral Student 11 8%
Other 28 19%
Unknown 21 15%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 37 26%
Medicine and Dentistry 36 25%
Biochemistry, Genetics and Molecular Biology 15 10%
Agricultural and Biological Sciences 10 7%
Nursing and Health Professions 5 3%
Other 13 9%
Unknown 28 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2020.
All research outputs
#1,914,665
of 18,197,021 outputs
Outputs from Clinical Pharmacology & Therapeutics
#338
of 3,720 outputs
Outputs of similar age
#24,593
of 216,398 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#5
of 33 outputs
Altmetric has tracked 18,197,021 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,720 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,398 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.